AUTL Autolus Therapeutics plc: Prakiraan rega marang bathi

Autolus Therapeutics (AUTL) specializes in developing advanced oncology treatments through genetic modifications. Holding exclusive patents for immune cell programming solidifies the company's role as an innovator and promises stable profits. This chart illustrates a P/E ratio of 0.00. Further growth depends on the efficiency of production expansion and flawless biomaterial logistics, provided there is sufficient capital.

autolus.com - Pangali mangsa ngarep rega marang bathi AUTL (periode 04.07.2022 - 13.11.2026)

Ringkesan rincian data analitis Autolus Corp (AUTL)

- kuotasi lan prakiraan analis:

Rega saham Autolus Therapeutics plc|AUTL - Rentang target analis

- data kapitalisasi saham perusahaan:

Biji pasar Autolus Therapeutics PLC|AUTL - Total Nilai Perusahaan

- statistik nilai buku emiten:

Nilai Akuntansi saben Saham Autolus Therapeutics|AUTL - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku autolus.com|AUTL - Gunggung Aset Perusahaan

- data tingkat utang lan likuiditas finansial:

Total Utang marang Modal Autolus Therapeutics|AUTL - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Autolus Therapeutics|AUTL - Utang perusahaan|Rasio utang marang kapitalisasi buku Autolus Therapeutics PLC|AUTL - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Autolus Therapeutics|Rasio cepet autolus.com

- rincian asil keuangan lan kelipatan valuasi:

AUTL - Bathi resik taunan|Proyeksi bathi mangsa ngarep Autolus Therapeutics|AUTL - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Autolus Pharma|AUTL - Rasio P/E diaturake wutah|Pangali EV/EBITDA Autolus Therapeutics PLC|AUTL - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Autolus Therapeutics|AUTL - Bathi saben saham sajroning taun lumaku|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan autolus.com|AUTL - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Autolus Therapeutics

- informasi babagan volume dodolan lan pendapatan:

AUTL - Pendapatan dodolan perusahaan

Analisis umum perusahaan:AUTL Autolus Therapeutics plc

The forward P/E ratio determines the relationship between current market capitalization and expected net income for the following year. For Autolus Therapeutics (AUTL), the value 0.00 reflects market expectations regarding the commercial launch of its first oncology drug and the development of logistics. By analyzing the company's forward P/E history, an investor can observe the valuation's reaction to business scaling. A low ratio may indicate either an undervaluation or operational risks.

Perusahaan pesaing

Pangali Forward P/E LEGN|Sana Biotechnology Inc (SANA) - Pangali forward rega marang bathi|Allogene Therapeutics Inc - Prakiraan rega marang bathi|Selecta Biosciences Inc. (RNAC) - Rasio prakiraan rega marang bathi|CLLS: Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi CRBU (cariboubio.com)|TIL: Pangali Forward P/E|Prakiraan rega marang bathi Genenta Science|IPSC (Century Tx) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Jasper Bio JSPR|Rega marang bathi mangsa ngarep Senti Biosciences, Inc. (SNTI)|Rega marang bathi mangsa ngarep ADAP (adaptimmune.com)|Rega marang bathi mangsa ngarep CERo Therapeutics Holdings CERO|Alaunos Therapeutics Inc. - Rega marang bathi mangsa ngarep|ACHL: Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi CRGX (CARGO Therapeutics, Inc)|PSTX: Pangali Forward P/E|Pangali forward rega marang bathi 2seventybio.com TSVT|GRCL (Gracell Biotechnologies Inc.) - Pangali Forward P/E